
Pfizer’s palbociclib most commonly used breast cancer drug in clinical trials
pharmafile | December 11, 2018 | News story | Manufacturing and Production, Sales and Marketing | Cancer, breast cancer, clinical trials, global data, oncology
Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData.
The drug, which was used in 4% of breast cancer clinical trials conducted in 2018, was investigated for its use as a combination therapy in the vast majority of cases.
Mohamed Abukar, Pharma Analyst at GlobalData, commented: “The vast majority of trials investigating palbociclib use combination therapy (83%) to assess progression-free survival. The tubulin inhibitor paclitaxel was investigated in 3.5% of clinical trials, primarily in combination regimens; only 6.3% of clinical trials investigate the agent as monotherapy, and involved comparing different routes of administration.”
Meanwhile 10.9% of all oncology trials were related to breast cancer between 1 January 2018 and 16 November 2018.
Overall, the majority of clinical trials were in Phase II (50.8%) while the US led in regards to the quantity of clinical trials they conducted with 22.4% of trials being done in United States. In comparison China, who came in second place, conducted 10.6% of clinical trials.
Louis Goss
Related Content

AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …

Clinical trials don’t just have a recruitment problem, they have an enrolment protection problem.
By Dr. Richard Graham Industry conversations about clinical trial participation tend to focus on awareness, …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …







